Pfizer Inc. (PFE) stock analysis

Healthcare · Drug Manufacturers - General

From the 10-K filed 2026-02-26

Business type: Franchise

How it makes money

Pfizer earns revenue primarily from the worldwide manufacture and sale of biopharmaceutical medicines and vaccines to patients and healthcare systems.

Pfizer operates as a research-based, global biopharmaceutical company generating revenue by discovering, developing, manufacturing, marketing, selling, and distributing biopharmaceutical products. Most of its revenues come from the manufacture and sale of these medical products across developed and emerging markets.

Revenues are driven by the commercial execution of its product portfolio, market demand for treatments that address feared diseases, and the ability of healthcare providers and patients to access and afford these therapies. Financial results are also influenced by pricing arrangements and contracting methods negotiated with payors, managed care entities, and governments.

What protects it: the moat

Pfizer relies on its product pipeline, marketed brands, and business development transactions to sustain its competitive position against rivals.

Management asserts that its competitive advantage is anchored in advancing its product pipeline, supporting marketed brands, and deploying capital responsibly into transactions and strategic business development opportunities.

The company also seeks to protect its position by scaling artificial intelligence across its business and continuously evaluating its asset portfolio through regular reviews. However, the filing discloses that competitive product launches can erode future sales and lead to product obsolescence, while external competitors continue to expand their research and development capabilities.

What growth costs

Pfizer reinvests capital into research and development, business development transactions, and multi-year cost realignment programs to drive future growth.

The company deploys capital to advance its product pipeline and pursues business development activities, such as acquisitions and in-licensing agreements, to strengthen its capabilities and portfolio offerings.

To manage its cost structure, Pfizer launched a multi-year, enterprise-wide cost realignment program in the fourth quarter of 2023 and expanded it in the first quarter of 2025 to drive operational efficiencies. Additionally, it announced a multi-year, multi-phased manufacturing optimization program in the second quarter of 2024 to reduce costs of goods sold.

What could damage it

Consolidated private payors and managed care entities can demand larger rebates or restrict formulary access, directly impairing product sales.

Private payors and managed care organizations possess increasing negotiating power due to industry consolidation. These entities employ cost-containment tools such as deductibles, utilization management, and formulary exclusions to control drug utilization.

If Pfizer fails to secure favorable formulary placement or must grant steep rebates and price concessions to maintain market access, its revenues and operating results will suffer permanent harm.

About Pfizer Inc.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

More on PFE

Other companies in Drug Manufacturers - General